{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Number of participants with disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","groups":[{"description":"(1) Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG000","title":"Arm A - Dose Level 1"},{"description":"(2) Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 3 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG001","title":"Arm A - Dose Level 2"},{"description":"(1) Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG002","title":"Arm B - Dose Level 1"},{"description":"(2) Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 each 6 weeks cycles.\n\nBelantamab Mafodotin, Cyclophosphamide and Dexamethasone: Study drug","id":"OG003","title":"Arm B - Dose Level 2"},{"description":"Once tolerability of the highest planned dose is established, patients will be assessed for response rate. The arm with acceptable toxicity and best response will be further assessed in the expansion cohort.","id":"OG004","title":"Phase II : Expansion Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase II of the expansion cohort was stopped with the FDA withdrawal of the drug approval and reluctance of patients to participate. 0 patients were enrolled in the Phase II expansion Cohort, therefore, there is no data to report in the data table.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of death from any cause, assessed up to 3 years","title":"Number of Participants With Disease Progression","type":"SECONDARY","unitOfMeasure":"Participants"}